P3 Health Partners (PIII) Q4 2025: $170M EBITDA Turnaround Anchored by Contracting and Cost Reset

March 27, 2026 | By EarningsIQ Research

P3 Health Partners set a bold 2026 profitability target, underpinned by a $170 million EBITDA swing driven by revamped payer contracts and disciplined cost structure. The company’s phased entry into a new Medicare Advantage market adds 29,000 members and a clear revenue runway, while operational and clinical integration remain central to long-term value creation. Investors should focus on execution risk as the company transitions from foundational restructuring to scalable growth and risk-bearing arrangements.

Summary

• Contracting Overhaul: Majority of EBITDA improvement is already embedded via payer renegotiations and CMS rate lifts.
• Operational Discipline: Structural cost actions and provider alignment drive a leaner, more accountable platform.
• Growth Pathway: New 29,000-member partnership sets up phased, low-volatility market expansion with future risk upside.

Performance Analysis

P3 Health Partners delivered a mixed 2025, with revenue essentially flat year-over-year as the company focused on foundation-building rather than top-line expansion. While reported adjusted EBITDA loss narrowed only modestly, normalized figures show a $44 million improvement—reflecting underlying operational and contractual progress. Capitated revenue per member per month (PMPM), a core managed care metric, increased 5% for the year and 9% in Q4, indicating better documentation and payer terms. However, medical margin deteriorated sharply in Q4, swinging negative as the company absorbed a reclassification of network expenses and continued to right-size its provider network.

Operating expenses fell 9% year-over-year after adjusting for a $10 million vendor cost reclassification, signaling tangible progress on cost containment. Notably, selective reinvestment in frontline operations and care management was maintained, balancing efficiency with future readiness. The company ended the year with $25 million in cash, underscoring the importance of working capital discipline as it pivots to growth and risk-bearing contracts in 2026.

• Revenue Quality Mix: Capitated revenue PMPM gains reflect improved contract economics and member risk coding, not just volume.
• Cost Structure Reset: Duplicate infrastructure and discretionary spend were targeted, yielding a leaner operating base.
• Medical Margin Volatility: Q4 margin compression exposes ongoing pressure in managing total cost of care during network overhaul.

Execution on contract renegotiations and operational streamlining is already reflected in 2026 guidance, with most improvement locked in by January and the remainder dependent on medical cost management and benefit design initiatives.

Executive Commentary

Strategic Positioning

1. Contracting and Revenue Optimization

P3’s 2026 turnaround is anchored in payer contract renegotiations—including premium increases, chargeback rationalization, and STARs-related adjustments. About 75% of the targeted $170 million EBITDA improvement is already run-rated, giving management high confidence in guidance. The company’s willingness to revisit legacy terms with payers and eliminate duplicative costs marks a fundamental shift toward sustainable revenue quality.

2. Provider Network Realignment

Provider alignment is central to P3’s value-based care model. Over half of members are now attributed to Tier 1 providers, which operate with higher clinical integration and accountability. This shift supports improved documentation, quality performance, and chronic care management—key to both medical margin and payer partnerships.

3. Smart Growth and Geographic Expansion

The Nebraska Blues partnership introduces 29,000 new managed lives—a 25% in-year membership boost. The phased “glide path” to risk allows P3 to build operational foundations before assuming full risk, with revenue potential exceeding $300 million at full ramp. Stand-up costs are funded by the deal structure, leveraging P3’s existing platform and minimizing financial drag during the entry phase.

4. Medical Cost Management Initiatives

Medical cost containment remains the largest controllable opportunity for margin expansion. Initiatives such as MedEx and chronic care programs are being scaled, with benefits expected to build through the year. The ability to standardize workflows and further integrate clinical data will be critical to sustaining improvements.

5. Quality and Clinical Enablement

Achieving four-star status across 70% of priority Medicare Advantage plans has direct revenue implications via STARs bonuses and strengthens payer relationships. P3’s care enablement model, embedding care coordination and utilization management within provider practices, is designed to proactively manage high-risk populations and reduce avoidable utilization.

Key Considerations

P3 Health Partners is at an inflection point, transitioning from foundational restructuring to disciplined, scalable growth. The company’s trajectory now hinges on execution of embedded contract improvements and the ability to manage medical costs while onboarding new geographies.

Key Considerations:

• Embedded Revenue Gains: Most of the 2026 EBITDA improvement is already reflected in payer contracts and CMS rate updates, reducing execution risk on the top line.
• Operational Leverage: Cost structure reset provides a leaner base, but maintaining discipline as growth resumes will be critical.
• Phased Risk Adoption: The Nebraska Blues partnership’s glide path strategy reduces volatility, but ultimate profitability depends on successful transition to risk-bearing arrangements.
• Clinical Integration Depth: Continued expansion of Tier 1 provider participation and workflow standardization is required to fully capture value-based care economics.

Risks

Execution risk looms largest as P3 pivots from cost takeout to operational scaling, especially in new geographies where provider alignment and data integration lag legacy markets. Medical margin volatility remains a concern, particularly if cost management initiatives underdeliver or if acute utilization spikes. Liquidity is stable for now, but working capital discipline must persist as risk-based contracts ramp. Regulatory and payer environment changes could also impact contract economics and revenue visibility.

Forward Outlook

For Q1 and full-year 2026, P3 Health Partners guided to:

• Adjusted EBITDA range of negative $20 million to positive $40 million, midpoint $10 million
• At-risk membership of 107,000 to 117,000
• Total revenue of $1.5 billion to $1.7 billion

Management highlighted:

• 75% of EBITDA improvement is locked in via already-executed contracts and CMS rates
• Remaining upside depends on scaling medical cost management and further contract optimization

Takeaways

P3’s 2026 story is about execution, not just aspiration. The company has reset its contract and cost base, but must now prove its ability to scale clinical programs and manage risk as new markets come online.

• Contracting and Cost Reset: Majority of improvement is already embedded, supporting guidance credibility.
• Provider and Clinical Alignment: Expansion of Tier 1 providers and care management programs is necessary to sustain margin gains.
• Growth Execution Watchpoint: Investors should monitor operational milestones and medical margin trends as new geographies are integrated and risk ramps up.

Conclusion

P3 Health Partners enters 2026 with structural improvements largely in place and a clear pathway to EBITDA breakeven. The focus now shifts to flawless execution in cost management, provider integration, and phased risk adoption. The credibility of the turnaround will hinge on delivering sustained medical margin improvement and operational discipline as growth resumes.

Industry Read-Through

P3’s results and strategy reflect a broader trend in value-based care: profitability and growth increasingly depend on contract sophistication, provider alignment, and the ability to manage total cost of care. The phased approach to risk in new markets is likely to become a model for other Medicare Advantage operators seeking to balance growth with volatility management. Payer-provider contract renegotiation, STARs-driven revenue optimization, and disciplined cost structures are now table stakes in the sector. Competitors and investors should watch for margin volatility as legacy arrangements are unwound and risk-based models scale.

PIII Healthcare Managed Care Value-Based Care Medicare Advantage Contracting Provider Alignment EBITDA